Brainstorm Cell Therapeutics Stock News

NEW YORK, March 14, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company w

NEW YORK, Feb. 28, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptance of a scientific abstract as a late-breaking oral presentation at the 2022 MDA…

Brainstorm Cell Therapeutics (BCLI) said the Brazilian Patent Office granted a patent covering a method of manufacturing MSC-NTF cells (NurOwn).The application is titled, "A method…

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph

NEW YORK, Jan. 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph

The market is being driven by a growing senior population, increased awareness of ALS, and an increasing incidence rate. The high cost of ALS therapy, on the other hand, may be an obstacle to the market throughout the projection period. North

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) with the stream of 9.41% also noticed, India Oragenics, Inc. (AMEX:OGEN) encountered a rapid change of -2.47% in the last hour of Thursdays trading session. The post Striking Stock: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), Oragenics, Inc. (AMEX:OGEN) appeared first on Stocks Equity .

Equities research analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report ($0.23) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Brainstorm Cell Therapeutics earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.24). Brainstorm Cell Therapeutics reported []

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) with the stream of -14.74% also noticed, India SentinelOne, Inc. (NYSE:S) encountered a rapid change of -1.46% in the last hour of Tuesdays trading session. The post Volume Movers: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), SentinelOne, Inc. (NYSE:S) appeared first on Stocks Equity .

Millennium Management LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 371,460 shares of the biotechnology companys stock, valued at approximately $1,412,000. Millennium Management LLC owned 1.02% of Brainstorm Cell Therapeutics []

Equities analysts forecast that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will announce ($0.23) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Brainstorm Cell Therapeutics earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.24). Brainstorm Cell Therapeutics reported earnings []

Northern Trust Corp decreased its holdings in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 83.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,761 shares of the biotechnology companys stock after selling 249,672 shares during the period. Northern Trust Corp owned 0.14% []

Charles Schwab Investment Management Inc. cut its holdings in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 85.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,287 shares of the biotechnology companys stock after selling 66,828 shares during the quarter. Charles Schwab Investment []

(RTTNews) - BrainStorm Cell Therapeutics Inc. (BCLI) reported new analyses from the phase 3 trial of NurOwn in amyotrophic lateral sclerosis. It showed that although the phase 3 trial did not reach statistical significance on the primary and secondary endpoints, pre-specified and post hoc analyses leveraging different methods of exploring the

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research